Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Tumor markers

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    703 result(s) found for: Tumor markers. Displaying page 1 of 36.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2016-004269-14 Sponsor Protocol Number: HP002-001 Start Date*: 2018-05-07
    Sponsor Name:Hamlet Pharma AB
    Full Title: A Randomized Placebo controlled Phase I/II Study Evaluating the Safety and Efficacy of Alpha1H in adult patients with non-muscle invasive bladder cancer awaiting transurethral surgery
    Medical condition: Non-muscle invasive bladder cancer awaiting transurethral surgery
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-004074-25 Sponsor Protocol Number: ABc2 Start Date*: 2020-08-12
    Sponsor Name:AZIENDA OSPEDALIERO-UNIVERSITARIA PISANA
    Full Title: A Phase II Open-Label Randomized COntrolled Pre-Surgical Feasibility Study of Antibiotic COmbinations in Early Breast Cancer
    Medical condition: We investigated, in a population of patients with breast cancer, the combined effect of azithrocyn, docyciclin and vitamin C on biomarkers associated with cell proliferation
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004865 10079328 Breast tumor excision LLT
    Population Age: Adults Gender: Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2013-000883-27 Sponsor Protocol Number: Rif_CVID_260611 Start Date*: 2013-08-16
    Sponsor Name:Oslo University hospital
    Full Title: EFFECTS OF RIFAXIMIN, BY MODULATION OF THE GUT MICROBIOTA, ON MARKERS OF SYSTEMIC INFLAMMATION IN PATIENTS WITH COMMON VARIABLE IMMUNODEFICIENCY - AN EXPLORATORY OPEN-LABEL RANDOMIZED CONTROLLED TRIAL
    Medical condition: Adult patients with the diagnosis of Common variable deficiency and fulfill the inclusion and exclusion criteria, will be invited to participate in the study.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-003336-37 Sponsor Protocol Number: HBA_001 Start Date*: 2018-06-25
    Sponsor Name:SGHL – SOCIEDADE GESTORA DO HOSPITAL DE LOURES, S.A - Hospital Beatriz Ângelo
    Full Title: CA2209-9G7: Phase II multi-institutional proof of concept single-arm trial of Nivolumab in the treatment of patients with platinum-recurrent or platinum-refractory metastatic germ cell tumors
    Medical condition: Metastatic germ cell tumors
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2019-001197-28 Sponsor Protocol Number: 201900180 Start Date*: 2019-07-31
    Sponsor Name:University Medical Center Groningen
    Full Title: Can 89Zr-atezolizumab PET scan identify patients with metastatic invasive lobular breast cancer who will respond to chemotherapy-immune checkpoint inhibition?
    Medical condition: Lobular metastatic breast cancer
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-005100-34 Sponsor Protocol Number: VX13-970-002 Start Date*: 2014-04-16
    Sponsor Name:Vertex Pharmaceuticals Incorporated
    Full Title: An Open-Label Study of the Safety, Tolerability, and Pharmacokinetic / Pharmacodynamic Profile of VX-970 as a Single Agent in Combination With Carboplatin in Subjects With Advanced Solid Tumors
    Medical condition: Cancer (malignant solid tumors)
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004864 10065147 Malignant solid tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2011-001812-80 Sponsor Protocol Number: 11-12-23/03-intern-6470 Start Date*: 2011-11-25
    Sponsor Name:Maastro Clinic
    Full Title: Non invasive imaging of [18F]HX4 with Positron-Emission-Tomography (PET) in Head and Neck Cancer.
    Medical condition: Patients with histological or cytological confirmed squamous cell carcinomas of the oral cavity, oropharynx, hypopharynx, larynx, T2-T3-T4, any N, M0
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067821 Head and neck cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2006-002978-21 Sponsor Protocol Number: OMEGA3 Start Date*: 2006-09-06
    Sponsor Name:AZIENDA SANITARIA OSPEDALIERA "S. GIOVANNI BATTISTA DI TORINO"
    Full Title: SPERIMENTAL STUDY ON THE CLINICAL EFFECT OF POLI UNSATURATED FATTY ACIDS w-3 AND ON THEIR ANTIFLAMMATORY AND ANTI OXIDANT ACTION IN LUNG CANCER PATIENTS DURING CHEMIOTHERAPY
    Medical condition: patients with indication to first line chemiotherapy
    Disease: Version SOC Term Classification Code Term Level
    9.1 10062042 Lung neoplasm LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-001270-33 Sponsor Protocol Number: GCTSK003 Start Date*: 2015-07-28
    Sponsor Name:Národný onkologický ústav
    Full Title: A treatment strategy of the Use of 1st line Chemotherapy in Patients with Poor-Prognosis Disseminated Non-Seminomatous Germ Cell Tumors based on tumor marker decline: A Phase II Trial of paclitaxel...
    Medical condition: Disseminated Non-Seminomatous Germ Cell Tumors.
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061184 Germ cell cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: SK (Completed)
    Trial results: View results
    EudraCT Number: 2017-000724-10 Sponsor Protocol Number: 60978 Start Date*: 2018-07-04
    Sponsor Name:Academic Medical Center
    Full Title: Targeting esophageal cancer with HDL nanoparticles: an imaging study
    Medical condition: Primary esophageal cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-007348-32 Sponsor Protocol Number: CSOM230D2203 Start Date*: 2009-05-06
    Sponsor Name:Novartis Pharma Services AG
    Full Title: An open label, multicenter, single arm study of pasireotide LAR in patients with rare tumors of neuroendocrine origin
    Medical condition: The following tumors are included: 1. NETs of the pancreas or duodenum: Insulinoma, Gastrinoma, VIPoma, glucagonoma, 2. Pituitary NETs: Thyrotropic-pituitary adenoma (TSH), Gonadotropic adenoma, Pr...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10062476 Neuroendocrine tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) DE (Completed) IT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2006-002877-30 Sponsor Protocol Number: CSOM230B2212 Start Date*: 2006-12-22
    Sponsor Name:NOVARTIS FARMA
    Full Title: An open label, multicenter, pilot phase II study of SOM230 s.c. in patients with duodeno-pancreatic (neuro) endocrine tumors and different pituitary diseases (Nelsonﾒs syndrome, non-functioning ad...
    Medical condition: duodeno-pancreatic (neuro) endocrine tumors and different pituitary diseases (Nelsonﾒs syndrome, non-functioning adenoma, TSH-adenoma,Gonadotroph adenoma, and PRL-adenoma)
    Disease: Version SOC Term Classification Code Term Level
    6.1 10035098 HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-001072-13 Sponsor Protocol Number: GETUG13 Start Date*: 2005-10-25
    Sponsor Name:UNICANCER
    Full Title: A risk-adapted strategy of the use of dose-dense chemotherapy in patient with poor-prognosis dissemined non-seminomatous germ cell tumors. GETUG 13 / 0206
    Medical condition: Non-Seminoma Germ Cell Tumor
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male
    Trial protocol: SK (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2021-006638-38 Sponsor Protocol Number: 2021/3282 Start Date*: 2022-05-18
    Sponsor Name:GUSTAVE ROUSSY
    Full Title: A prospective program aiming at improving outcome for young adults with poor-prognosis non seminomatous germ-cell tumors - VAPOR (GETUG T06)
    Medical condition: Non-seminomatous germ-cell tumors (including testis, retroperitoneal and mediastinal primaries) with a disseminated disease (clinical stages II or III according to AJCC 8th edition) and classified ...
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Male
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2013-005559-34 Sponsor Protocol Number: AIO-PAK-0313 Start Date*: 2015-01-19
    Sponsor Name:AIO-Studien-gGmbH
    Full Title: Neoadjuvant plus adjuvant or only adjuvant nab-Paclitaxel plus Gemcitabine for resectable pancreatic cancer - The AIO-NEONAX trial (AIO-PAK-0313) A prospective, randomized, controlled, phase II st...
    Medical condition: Resectable pancreatic cancer
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10033608 Pancreatic cancer resectable LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2022-002599-35 Sponsor Protocol Number: 2022-1-58-002 Start Date*: 2022-10-21
    Sponsor Name:Centre de Lutte Contre le Cancer Eugène Marquis
    Full Title: Contribution of [18F]DPA-714 PET for grading and exploration of the inflammatory microenvironment of glioma, a pilot study.
    Medical condition: glioma (grade OMS II à IV)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018338 Glioma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2022-003787-24 Sponsor Protocol Number: PM-CARE-PNRR-MAD-2022-12375905 Start Date*: 2023-04-20
    Sponsor Name:OSPEDALE SAN RAFFAELE
    Full Title: Precision Medicine in patients with unresectable CholAngiocarcinoma; RadioEmbolization and combined biological therapy (Single arm, multicenter phase II study investigating the efficacy and safety...
    Medical condition: Unresectable intrahepatic cholangiocarcinoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073077 Intrahepatic cholangiocarcinoma LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008593 Cholangiocarcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2006-000897-65 Sponsor Protocol Number: MN2 Start Date*: 2006-02-20
    Sponsor Name:AZIENDA OSPEDALIERA ARCISPEDALE S. MARIA NUOVA
    Full Title: Therapy of tumors SSTR2 expressing using somatostatine analogs labeled with 90Y and 177 Lu.
    Medical condition: Diagnosis of tumor classified as expressing SSRT2, the main class of tumors to be included in the study are advanced and metastatic neuroendocrine tumors but also breast, lungs and thyroid cancers...
    Disease: Version SOC Term Classification Code Term Level
    6.1 10052399 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-000224-17 Sponsor Protocol Number: 11-36-14/12 Start Date*: 2014-09-15
    Sponsor Name:MAASTRO Clinic
    Full Title: Non invasive imaging of [18F]HX4 with Positron-Emission-Tomography (PET) in Cervix Cancer.
    Medical condition: Eligible patients with squamous cell carcinoma, adenocarcinoma or adenosquamous carcinoma (FIGO stage IB – IVA), to be treated with curative radiation treatment either or not combined with concurr...
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2005-002132-94 Sponsor Protocol Number: CZOL446EDE28 Start Date*: 2008-08-18
    Sponsor Name:Novartis Pharma GmbH
    Full Title: „Effect of intravenous Zoledronic Acid on Bone Metabolism given over 4 month in patients with prostate cancer or breast cancer and bone metastasis. A prospective, single-arm multicenter study” (Z...
    Medical condition: Patients with prostate or breast cancer with bone metastasis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10036910 Prostate cancer NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 03 07:13:41 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA